SMARCA2 and breast cancer: Despite the tumour suppressive role of ARID1A and loss of BRG1 activity in ARID1A-perturbed ER+ breast cancers (Nagarajan et al., 2020), BRG1 and BRM may present as efficient targets in other subtypes due to their crucial roles in promoting progression and mediating resistance to chemotherapy.